Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
India’s Small Pharma Sector on the Brink: Over 60% of Units May Close Under New Quality Rules
The Ministry of Health and Family Welfare strengthened GMP norms after a series of high-profile public health incidents, including contamination cases linked to cough syrups that resulted in child fatalities both in India and abroad. These tragic outcomes crystallised the urgent need for more rigorous quality controls on drug manufacturing processes.
- By Newsdesk
- New Delhi
- Dec 16, 2025
A sweeping regulatory overhaul aimed at strengthening drug quality across India’s pharmaceutical industry could inadvertently force the closure of a majority of the country’s smaller drug manufacturers by the end of this month.
Industry insiders warn that more than 60% of micro, small, and medium pharmaceutical units, roughly 8,500 out of about 10,500 registered drug manufacturers nationwide may be unable to meet updated compliance requirements and could shut operations by December 31. These compliance standards, part of revised Good Manufacturing Practices (GMP) under the Drugs and Cosmetics Act, are designed to align Indian production with global benchmarks but present significant challenges for smaller players.
The Ministry of Health and Family Welfare strengthened GMP norms after a series of high-profile public health incidents, including contamination cases linked to cough syrups that resulted in child fatalities both in India and abroad. These tragic outcomes crystallised the urgent need for more rigorous quality controls on drug manufacturing processes.
Most small and medium units operate a single facility and lack the infrastructure, capital, or technical capacity to rapidly upgrade plants, install advanced quality systems, and satisfy stringent documentation and process requirements. With the December 31 deadline looming, many firms have neither completed necessary upgrades nor secured the regulatory approvals needed to continue production.
According to industry executives, the impact of widespread closures may extend far beyond factory gates. A shutdown of this scale — affecting units that contribute an estimated ₹75,000 crore to India’s ₹2.5 lakh crore domestic drug market — could disrupt the supply of core medicines such as antibiotics, anti-hypertensives, analgesics, diabetes treatments, and common cough and cold drugs. These medicines are crucial not only domestically but also for low- and middle-income countries that rely on Indian exports.
Small-firm associations have repeatedly pressed the government for deadline extensions and financial support, arguing that the required upgrades demand significant investment and skilled manpower that many MSMEs cannot readily afford. However, regulatory authorities have so far remained firm, emphasising that compliance is essential to safeguard public health and restore confidence in Indian pharmaceuticals on the global stage.
As late-stage inspections intensify across states and Union Territories, analysts say the situation highlights the broader tension between enforcing global quality standards and sustaining the viability of India’s sprawling network of small medicine producers.